NCT02092116 - Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions

HIV I Infection

Interventions

DRUG

Romidepsin

Latency reversing agent

BIOLOGICAL

Vacc-4x

Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

BIOLOGICAL

rhuGM-CSF

Granulocyte macrophage colony stimulating factor as a local adjuvant

Trial Locations (1)

Aarhus University Hospital, Skejby Sygehus, Aarhus N